Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

ELELYSO Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Elelyso patents expire, and when can generic versions of Elelyso launch?

Elelyso is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-eight patent family members in twenty-five countries.

The generic ingredient in ELELYSO is taliglucerase alfa. One supplier is listed for this compound. Additional details are available on the taliglucerase alfa profile page.

US ANDA Litigation and Generic Entry Outlook for Elelyso

  Start Trial

Elelyso was eligible for patent challenges on May 1st, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 24th, 2024. This may change due to patent challenges or generic licensing.

Summary for ELELYSO
International Patents:78
US Patents:3
Suppliers / Packagers: 1
Clinical Trials: 2
Drug Prices: Drug price information for ELELYSO
DailyMed Link:ELELYSO at DailyMed
Drug patent expirations by year for ELELYSO
Drug Prices for ELELYSO

See drug prices for ELELYSO

Generic Entry Opportunity Date for ELELYSO
Generic Entry Date for ELELYSO*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ELELYSO

Identify potential brand extensions & 505(b)(2) entrants

Ari ZimranPhase 4
PfizerPhase 4

See all ELELYSO clinical trials

Pharmacology for ELELYSO

US Patents and Regulatory Information for ELELYSO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer ELELYSO taliglucerase alfa POWDER;INTRAVENOUS 022458-001 May 1, 2012 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer ELELYSO taliglucerase alfa POWDER;INTRAVENOUS 022458-001 May 1, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Pfizer ELELYSO taliglucerase alfa POWDER;INTRAVENOUS 022458-001 May 1, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.